Overview

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at subject incidence of adverse events.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Epoetin Alfa